Biostem Technologies Inc
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wou… Read more
Market Cap & Net Worth: Biostem Technologies Inc (BSEM)
Biostem Technologies Inc (OTCQB:BSEM) has a market capitalization of $138.98 Million ($138.98 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #41561 globally and #13512 in its home market, demonstrating a -11.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biostem Technologies Inc's stock price $8.29 by its total outstanding shares 16765341 (16.77 Million).
Biostem Technologies Inc Market Cap History: 2015 to 2025
Biostem Technologies Inc's market capitalization history from 2015 to 2025. Data shows growth from $238.91 Million to $138.98 Million (11.53% CAGR).
Biostem Technologies Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biostem Technologies Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.77x
Biostem Technologies Inc's market cap is 0.77 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
7.29x
Biostem Technologies Inc's market cap is 7.29 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $238.91 Million | $151.54K | -$2.38 Million | 1576.56x | N/A |
| 2016 | $168.49 Million | $607.22K | -$3.96 Million | 277.48x | N/A |
| 2017 | $201.18 Million | $328.53K | -$4.84 Million | 612.38x | N/A |
| 2018 | $53.65 Million | $1.02 Million | -$7.59 Million | 52.74x | N/A |
| 2019 | $41.91 Million | $2.63 Million | -$6.34 Million | 15.93x | N/A |
| 2020 | $24.31 Million | $2.52 Million | -$2.39 Million | 9.64x | N/A |
| 2021 | $17.44 Million | $4.34 Million | -$1.45 Million | 4.02x | N/A |
| 2022 | $50.13 Million | $6.88 Million | -$7.07 Million | 7.29x | N/A |
| 2023 | $98.24 Million | $16.69 Million | -$8.48 Million | 5.89x | N/A |
| 2024 | $232.54 Million | $301.83 Million | $31.88 Million | 0.77x | 7.29x |
Competitor Companies of BSEM by Market Capitalization
Companies near Biostem Technologies Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Biostem Technologies Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Biostem Technologies Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Biostem Technologies Inc's market cap moved from $238.91 Million to $ 138.98 Million, with a yearly change of 11.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $138.98 Million | -40.23% |
| 2024 | $232.54 Million | +136.69% |
| 2023 | $98.24 Million | +95.99% |
| 2022 | $50.13 Million | +187.50% |
| 2021 | $17.44 Million | -28.28% |
| 2020 | $24.31 Million | -42.00% |
| 2019 | $41.91 Million | -21.88% |
| 2018 | $53.65 Million | -73.33% |
| 2017 | $201.18 Million | +19.40% |
| 2016 | $168.49 Million | -29.47% |
| 2015 | $238.91 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Biostem Technologies Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $138.98 Million USD |
| MoneyControl | $138.98 Million USD |
| MarketWatch | $138.98 Million USD |
| marketcap.company | $138.98 Million USD |
| Reuters | $138.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.